New Enzyme Therapy OK'd for Pompe Disease

(MedPage Today) -- The FDA approved avalglucosidase alfa-ngpt (Nexviazyme) on Friday as a new enzyme replacement therapy for Pompe disease.
Avalglucosidase alfa is an intravenous drug that targets the M6P receptor, and is indicated for late-onset...